Source:http://linkedlifedata.com/resource/pubmed/id/12467135
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-12-6
|
pubmed:abstractText |
There is increasing evidence that individual isomers of conjugated linoleic acid (CLA) may have unique biological or biochemical effects. A primary objective of this study was to determine whether there might be differences in the anticancer activity of 9,11-CLA and 10,12-CLA. This was achieved by evaluating the reduction in premalignant lesions and carcinomas in the mammary gland of rats that had been treated with a single dose of methylnitrosourea and given 0.5% of either highly purified CLA isomer in the diet. Our results showed that the anticancer efficacies of the two isomers were very similar. At 6 wk after carcinogen administration, the total number of premalignant lesions was reduced by 33-36%. At 24 wk, the total number of mammary carcinomas was reduced by 35-40%. The concentration of each CLA isomer and its respective metabolites was analyzed in the mammary fat pad. Tissue level of 10,12-CLA was much lower than that of 9,11-CLA. The pool of metabolites from each isomer was very similar between the two groups and represented only a small fraction of total conjugated diene fatty acids. Feeding of 9,11-CLA resulted in minimal changes in other unsaturated fatty acids. In contrast, feeding of 10,12-CLA produced a wider spectrum of perturbations. Small but significant increases in 16:1 and 16:2 were detected; these were accompanied by decreases in 20:2, 20:3, 20:4, 22:4, and 22:6. The above observation suggests that 10,12-CLA might be more potent than 9,11-CLA in interfering with elongation and desaturation of linoleic and linolenic acids. In summary, our study showed that, at the 0.5% dose level, the anticancer activity of 9,11-CLA and 10,12-CLA was very similar, even though accumulation of 10,12-CLA in the mammary tissue was considerably less than that of 9,11-CLA. These confounding changes of the other unsaturated fatty acids in contributing to the effect of 10,12-CLA need to be clarified.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/10,12-octadecadienoic acid,
http://linkedlifedata.com/resource/pubmed/chemical/9,11-linoleic acid,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Unsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Linoleic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Linoleic Acids, Conjugated,
http://linkedlifedata.com/resource/pubmed/chemical/Methylnitrosourea
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0163-5581
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
52-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12467135-Animals,
pubmed-meshheading:12467135-Carcinoma, Intraductal, Noninfiltrating,
pubmed-meshheading:12467135-Fatty Acids, Unsaturated,
pubmed-meshheading:12467135-Female,
pubmed-meshheading:12467135-Linoleic Acids,
pubmed-meshheading:12467135-Linoleic Acids, Conjugated,
pubmed-meshheading:12467135-Mammary Glands, Animal,
pubmed-meshheading:12467135-Mammary Neoplasms, Experimental,
pubmed-meshheading:12467135-Methylnitrosourea,
pubmed-meshheading:12467135-Precancerous Conditions,
pubmed-meshheading:12467135-Rats,
pubmed-meshheading:12467135-Rats, Sprague-Dawley,
pubmed-meshheading:12467135-Time Factors
|
pubmed:year |
2002
|
pubmed:articleTitle |
Conjugated linoleic acid isomers and mammary cancer prevention.
|
pubmed:affiliation |
Department of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Clement.Ip@roswellpark.org
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|